pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 13·1 min read
save

UnitedHealth touts home-care audit but its 97% justification claim faces scrutiny as insurers sue CMS over MA ratings

Jul 13, 2026·read at STAT ↗RegulatoryNegative

UnitedHealth Group promoted a new audit that claims 97% of diagnoses recorded for its Medicare Advantage members during home visits are supported by medical records. The company presented the findings as evidence of high quality care.

However, the audit’s results are not as clear-cut as UnitedHealth suggests, raising questions about the usefulness of the data. Critics argue that the methodology and conclusions may be overstated.

At the same time, additional health insurers have filed lawsuits against the Centers for Medicare & Medicaid Services, challenging the quality-rating system used for Medicare Advantage plans. These legal actions add pressure on regulators and insurers alike.

The combined scrutiny of UnitedHealth’s audit and the broader lawsuits highlights ongoing concerns about transparency and accountability in Medicare Advantage programs.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: UnitedHealth’s questionable review, and more MA stars lawsuits”

read at STAT ↗
489 words · retrieved Jul 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Beam Therapeutics Inc.PATHROCHE

related stories

  • Jul 13STAT+: All eyes on data on Biogen’s tau therapySTAT
  • Jul 13STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to comeSTAT
  • Jul 12STAT+: Tau in the spotlight at Alzheimer’s conferenceSTAT
  • Jul 10STAT+: Roche ends Huntington’s gene-silencing programsSTAT
  • 9h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace